Nuveen LLC Takes $4.39 Million Position in Denali Therapeutics Inc. $DNLI

Key Points

• Nuveen LLC has acquired a significant stake in Denali Therapeutics, purchasing 322,945 shares valued at approximately $4.39 million, now owning 0.22% of the company.
• Several institutional investors have increased their positions in Denali, with 92.92% of the stock currently owned by institutional investors.
• Analysts have mixed views on Denali Therapeutics, with price targets ranging from $27.00 to $33.00 and a general average rating of "Buy" from multiple analysts.

Nuveen LLC bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 322,945 shares of the company's stock, valued at approximately $4,390,000. Nuveen LLC owned 0.22% of Denali Therapeutics as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Entropy Technologies LP purchased a new stake in shares of Denali Therapeutics during the first quarter worth $152,000. Invesco Ltd. raised its stake in shares of Denali Therapeutics by 55.9% during the 1st quarter. Invesco Ltd. now owns 189,427 shares of the company's stock worth $2,575,000 after purchasing an additional 67,949 shares in the last quarter. TD Asset Management Inc raised its stake in shares of Denali Therapeutics by 16.1% during the 1st quarter. TD Asset Management Inc now owns 308,580 shares of the company's stock worth $4,195,000 after purchasing an additional 42,828 shares in the last quarter. Knights of Columbus Asset Advisors LLC lifted its holdings in shares of Denali Therapeutics by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock valued at $548,000 after buying an additional 1,058 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Denali Therapeutics in the 1st quarter valued at approximately $254,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Stock Performance

Denali Therapeutics stock traded down $0.38 on Monday, reaching $15.27. 1,886,628 shares of the stock were exchanged, compared to its average volume of 1,791,339. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33. The firm has a fifty day moving average price of $14.48 and a two-hundred day moving average price of $14.73. The stock has a market cap of $2.23 billion, a PE ratio of -5.45 and a beta of 1.23.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same period last year, the company earned ($0.59) earnings per share. Sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total value of $7,429,230.00. Following the transaction, the chief executive officer directly owned 253,071 shares of the company's stock, valued at $3,796,065. The trade was a 66.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alexander O. Schuth sold 2,937 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider owned 242,346 shares of the company's stock, valued at approximately $3,291,058.68. This trade represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 501,962 shares of company stock valued at $7,520,799 in the last 90 days. 12.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. HC Wainwright cut their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Robert W. Baird dropped their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Wedbush reduced their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Morgan Stanley decreased their price objective on shares of Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating for the company in a report on Monday, August 18th. Finally, Bank of America cut their target price on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $33.62.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.